我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

普拉格雷在冠心病介入治疗中的研究进展

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2012年第4期
页码:
541-543
栏目:
综述
出版日期:
2012-08-25

文章信息/Info

Title:
Application of prasugrel in coronary interventional therapy
作者:
李岱旭 综述; 卢 琳 审阅
(济南市第四人民医院心内科，山东 济南 250031)
Author(s):
LI Dai-xu;  LU Lin
(Department of Cardiology, Jinan Fourth People’s Hospital, Jinan 250031, Shandong, China)
关键词:
普拉格雷; 冠状动脉疾病; 介入治疗
Keywords:
prasugrel;  coronary disease;  percutaneous coronary intervention
分类号:
R973
DOI:
-
文献标识码:
A
摘要:
口服双重抗血小板药物阿司匹林加噻吩吡啶，已获准在经皮冠状动脉介入治疗（PCI）中使用。第二代噻吩吡啶类衍生物氯吡格雷是给予PCI患者双重抗血小板治疗的选择性药物。但是，氯吡格雷存在两个缺陷：①氯吡格雷需要代谢产生其活性的形式，故抗血小板活性延迟；②已证明不同患者给予氯吡格雷后的反应存在很大差异性。为了克服氯吡格雷的上述缺陷，新一代更有效的普拉格雷（即第三代噻吩吡啶类衍生物），临床评价其可以快速起效。本文对第三代口服噻吩吡啶普拉格雷进行了综述，旨在总结普拉格雷的利弊并概述该药在临床使用中最谨慎的方案。
Abstract:
Dual oral antiplatelet therapy, aspirin plus thienopyridine, has been permitted to be used in percutaneous coronary intervention (PCI) procedures. Clopidogrel is the thienopyridine of choice for dual antiplatelet therapy in patients treated with PCI. However, there are two deficiencies with clopidogrel: (1) clopidogrel's antiplatelet activity is delayed because the drug needs to be metabolized into its active form, and (2) variability in patient response to clopidogrel has been confirmed. To overcome these limitations of clopidogrel, a new generation of more potent inhibitors of P2Y12 receptors with a more rapid onset of action has been introduced for clinical evaluation. This article, a nonexhaustive review of the literature on prasugrel, a third-generation oral thienopyridine, summarizes the current knowledge about the benefits and risks of prasugrel and outlines the most prudent strategies for clinical use of this drug.

参考文献/References

[1]荆亚萍,申东升,邓爵安,等.新一代血小板抑制剂-普拉格雷[J].国际药学研究杂志,2008,35(5):373-376.

[2]王国华,申东升,熊维.抗凝血新药立伐沙班[J].中国新药杂志,2009,18(6):494-496.

[3]赵树梅,李虹伟.氯吡格雷无反应:从基因到临床[J].心脏杂志,2011,23(5):664-666.

[4]Farid NA,Smith RL,Gillespie TA,et al.The disposition of prasugrel,a novel thienopyridine, in humans[J].Drug Metab Dispos,2007,35(7):1096-1104.

[5]Jakubowski JA,Winters KJ,Naganuma H,et al.Prasugrel:A novel thienopyridine antiplatelet agent[J].Cardiovasc Drug Rev,2007,25(4):357-374.

[6]Jakubowski JA,Winters KJ,Naganuma H.Prasugrel:A novel thienopyridine antiplatelet agent[J].Cardiovasc Drug Rev,2007,25(4):357-374.

[7]Brandt JT,Payne CD,Wiviott SD,et al.A comparison of prasugrel and clopidogrel loading doses on platelet function:Magnitude of platelet inhibition is related to active metabolite formation[J].Am Heart J,2007,153(1):e9-e16.

[8]Wallentin L,Varenhorst C, James S,et al.Prasugrel achieves greater and faster and P2Y receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease[J].Eur Heart J,2008,29(1):21-30.

[9]Brandt JT,Payne CD,Wiviott SD,et al.A comparison of prasugrel and clopidogrelloading doses on platelet function:Magnitude of platelet inhibition is related to active metabolite formation[J].Am Heart J, 2007,153(1):e9-e16.

[10]Wiviott SD,Braunwald E,McCabe CH,et al.Prasugrel versus clopidogrel in patients with acute coronary syndromes[J].N Eng J Med,2007,357(20):2001-2015.

[11]Wiviott SD,Braunwald E,McCabe CH,et al.Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial:a sub- analysis of a randomised trial[J].Lancet,2008,371(9621):1353-1363.

[12]Donahoe SM,Stewart GC,McCabe CH,et al.Diabetes and mortality following acute coronary syndromes[J].JAMA,2007,298(7):765-775.

[13]Motovska Z,Widimsky P,Petr R,et al.Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin’s advantage and the smoking “paradox”[J].J Cardiovasc Pharmaco,2009,53(5):368-372.

[14]Erlinge D,Varenhorst C,Braun OO,et al.Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo[J].J Am Coll Cardiol,2008,52(24):1968-1977.

[15]Wiviott SD,Braunwald E,Angiolillo DJ,et al.Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with dia- betes mellitus in TRITON-TIMI 38[J].Circulation,2008,118(16):1626-1636.

[16]陈 航.抗血小板药物新进展[J].心血管病学进展， 2009,30(1):105-108.

备注/Memo

备注/Memo:
收稿日期：2011-12-14.作者简介:李岱旭，住院医师，学士Email:waiting99@163.com
更新日期/Last Update: 2012-07-20